Amacathera is a company that brings together commercial leaders, researchers, and biotechnology experts to develop therapeutics aimed at improving patient outcomes.

Amacathera

AmacaThera is a Toronto-based biotechnology company focused on developing and commercializing a unique, injectable hydrogel platform technology for a wide range of medical applications.

Based on the research of world-renowned biomaterials scientist, Dr. Molly Shoichet, AmacaThera is commercializing combination products at the interface of biomaterials and pharmaceuticals.

We have developed a platform technology which addresses the critical problem of sustaining therapeutic delivery of pharmacological agents for multiple disease areas. 

Currently, we have developed a combination product for post-operative pain, which is our company's lead project.

Johnson & Johnson Robotics and Digital Solutions

Viva BioInnovator

BDC Capital’s Women in Technology Venture Fund

CR Capital Management

Sprout BioVentures

StandUp Ventures

Lumira Ventures

MaRS Investment Accelerator Fund

MBX Capital

Inveready

AmacaThera

AmacaThera Updates - August 2024

Our Business Development Lead Darren Rodenhizer, PhD has prepared an update on our clinical and business development achievements so far in 2024, with an eye toward our strategy for 2025.

We have also launched a quarterly newsletter that will provide regular updates like this on our progress - you can sign up for the newsletter by visiting our website: www.amacathera.ca

AmacaThera doses First In Human Study to Evaluate, AMT-143, for Non-opioid Treatment of Post-operative Pain

Read the press release here:

https://lnkd.in/e2eaExBX

Congratulations to our Co-Founder and CSO, Molly Shoichet on being named the inaugural Pamela and Paul Austin Chair in Precision and Regenerative Medicine at the University of Toronto!

#precisionmedicine
#regenerativemedicine
#toronto

Congratulations to our Co-Founder and Chief Science Officer Molly Shoichet and team on launching BioNetHub -- $19M in funding to address the HQP shortage in #biomanufacturing.

Great presentation by Darren at Pharma Partnering Summit, San Diego

AMAC

CA:AMACATHERA

Amacathera